Jun 27, 2022 8:30am EDT Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
Jun 24, 2022 8:30am EDT Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland
May 16, 2022 8:55am EDT Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th
May 13, 2022 8:30am EDT Artelo Biosciences to Present at MicroCap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th
May 12, 2022 8:30am EDT Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 25, 2022 7:30am EDT Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York
Apr 13, 2022 8:30am EDT Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
Mar 28, 2022 9:25am EDT Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer
Mar 22, 2022 9:00am EDT Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th
